Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;87(2):289-294.
doi: 10.1007/s00280-020-04203-z. Epub 2021 Jan 3.

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Malvi Savani  1 , Katti Woerner  2 , Lihong Bu  3 , Mark Birkenbach  3 , Keith M Skubitz  4   5
Affiliations
Review

Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review

Malvi Savani et al. Cancer Chemother Pharmacol. 2021 Feb.

Abstract

Doxorubicin is one of the most active drugs for sarcoma. Pegylated liposomal doxorubicin (PLD) is a unique formulation of doxorubicin, which carries a more favorable toxicity profile in comparison with free doxorubicin. The main toxicity of PLD is hand-foot syndrome. Unlike free doxorubicin, PLD is unlikely to cause alopecia, nausea, myelosuppression, or cardiotoxicity. Additionally, no premedications are required. We describe the case of a 50-year-old man with advanced retroperitoneal liposarcoma who developed irreversible PLD-associated progressive renal failure requiring chronic hemodialysis due to a thrombotic microangiopathy. No cardiotoxicity was noted 84 months after he initiated PLD. This case describes a lesser known toxicity of PLD and may be a toxicity of long-term treatment with other liposomal drugs.

Keywords: Doxorubicin; Renal toxicity; Sarcoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Alberts DS et al (2004) Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31(6 Suppl 13):53–90 - DOI
    1. Gabizon A et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54(4):987–992 - PubMed
    1. Northfelt DW et al (1996) Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 36(1):55–63 - DOI
    1. Skubitz KM et al (2017) Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol 80(4):787–798 - DOI
    1. Savani M, Murugan P, Skubitz KM (2019) Long-term cure of soft tissue sarcoma with pegylated-liposomal doxorubicin after doxorubicin and ifosfamide failure. Clin Sarcoma Res 9:1 - DOI

MeSH terms

Supplementary concepts

LinkOut - more resources